LOS ANGELES, Feb. 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma Ltd. (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that bought securities between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”). Quantum investors have until February 23, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their l ...

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. (“Quantum” or the “Company”) (NASDAQ: QNTM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether ...

Group 1 - A class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. regarding potential securities fraud or unlawful business practices by the company and its officers [1][2] - Investors have until February 23, 2026, to request to be appointed as Lead Plaintiff if they purchased Quantum securities during the Class Period [2] - The lawsuit alleges that certain financial institutions engaged in manipulative trading practices, specifically spoofing sell orders to create a false impression of Quantum's stock price decline [4] Group 2 - The defendants in the lawsuit include CIBC World Markets, RBC Dominion Securities, and Royal Bank of Canada, among others, who are accused of deceiving investors into selling shares at artificially low prices [4] - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud [5]

Core Viewpoint - A class action lawsuit has been filed against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC) for allegedly defrauding investors by executing manipulative trades that artificially deflated the price of Quantum Biopharma Ltd. (Quantum) securities [1][3]. Summary by Sections Lawsuit Details - The lawsuit seeks to recover damages for alleged violations of federal securities laws on behalf of all individuals and entities that sold Quantum securities between January 6, 2021, and October 15, 2025, inclusive [2]. - The Complaint alleges that Defendants engaged in thousands of spoofed sell orders to create a false appearance of declining stock prices, deceiving investors into selling shares at artificially depressed prices [3]. Allegations Against Defendants - Defendants are accused of making materially false and misleading statements and failing to disclose manipulative trading practices [3]. - The manipulative orders were designed to induce investors to sell their shares at lower prices, after which the Defendants purchased shares at these artificially deflated levels to profit from the scheme [3]. Next Steps for Investors - Investors who suffered losses in Quantum have until February 23, 2026, to request to be appointed as lead plaintiff in the class action [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Legal Representation - Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Insights - Quantum BioPharma has completed oral dosing of Lucid-21-302 (Lucid-MS) in both 180-day toxicity and toxicokinetic studies, which will support the Investigational New Drug (IND) application with the US FDA and the design of a Phase 2 trial for multiple sclerosis (MS) patients [1][2][3] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates at various development stages [1][3] - The company’s lead compound, Lucid-MS, is a patented new chemical entity that has shown potential in preventing and reversing myelin degradation in preclinical models of MS [3] Development Progress - The completion of the 180-day toxicity studies is a significant milestone, bringing the company closer to initiating the Phase 2 trial of Lucid-MS for MS patients [2][3] - The company is optimistic about the potential of Lucid-MS as a first-in-class treatment to prevent disease progression and inhibit demyelination in MS [3] Strategic Investments - Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is associated with the unbuzzd™ product, and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [3] - The company also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3]

Core Insights - Several biotechnology and life sciences companies experienced significant gains in after-hours trading, indicating strong investor interest in recent clinical and corporate developments [1] Company Summaries - Kura Oncology, Inc. (KURA) saw its shares rise to $10.57, an increase of 7.42% (+0.73), likely due to positive investor sentiment following the announcement of new data from its KOMET-007 Phase 1a/1b trial, which showed a favorable safety profile and encouraging antileukemic activity for its treatment regimen in acute myeloid leukemia patients [2] - SOPHiA GENETICS SA (SOPH) closed after hours at $4.85, gaining 5.21% (+0.24), with continued investor interest stemming from its collaboration with Complete Genomics to co-market precision oncology testing solutions [3] - Elutia Inc. (ELUT) experienced modest gains, with shares rising to $0.6045, up 3.10% (+0.0182), reflecting steady investor interest in the micro-cap biotech sector [4] - RenovoRx, Inc. (RNXT) added 2.47% (+0.02) to close at $0.9530, with recent news of its abstract submission acceptance for the ASCO Gastrointestinal Cancers Symposium 2026, where it will present findings from its ongoing Phase III trial [5] - Kodiak Sciences Inc. (KOD) posted a notable gain, climbing to $27.41, up 5.42% (+1.41), following the successful closing of a public offering that generated approximately $184 million in gross proceeds [6] - Day One Biopharmaceuticals, Inc. (DAWN) rose to $9.55, gaining 3.35% (+0.31), continuing to attract investor attention focused on oncology innovation [7] - Quantum BioPharma Ltd. (QNTM) advanced to $9.23, up 3.82% (+0.34), following the closing of a non-brokered private placement that raised gross proceeds of $750 [8]

Core Viewpoint - Quantum BioPharma Ltd. is facing a class action lawsuit alleging stock manipulation that has materially harmed its shareholders between January 6, 2021, and October 15, 2025 [1] Company Overview - Quantum BioPharma Ltd. (NASDAQ: QNTM) is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3] - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis [3] - Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is involved in the marketing of its product unbuzzd™ and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty rate will drop to 3% [3] Legal Actions - Shareholder Paul Durkacz has initiated a class action lawsuit against Quantum BioPharma, claiming that investors were victims of stock manipulation [1] - Quantum BioPharma intends to seek appointment as a lead plaintiff in the class action to protect its shareholders [2] Strategic Investments - The company maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial properties [3]

Core Viewpoint - Quantum BioPharma Ltd. has successfully closed a non-brokered private placement, issuing 30 Class A Multiple Voting Shares at a price of $25 each, resulting in gross proceeds of $750 million [1][2]. Offering Details - The securities issued are subject to a statutory hold period of four months plus a day from issuance as per Canadian securities laws [2]. - Proceeds from the offering will be utilized for general working capital purposes [2]. Related Party Transactions - Xorax Family Trust and Fortius Research and Trading Corp., both associated with company insiders, purchased all Class A Multiple Voting Shares in the offering, qualifying as a related-party transaction under MI 61-101 [3]. - The company has relied on exemptions from formal valuation and minority shareholder approval requirements as the transaction did not exceed 25% of the company's market capitalization [3]. Corporate Update - The company has terminated its at-the-market offering agreement with H.C. Wainwright & Co., effective December 6, 2025, with the termination taking effect on December 20, 2025 [16]. - No Class B Subordinate Voting Shares have been sold under the previous sales agreement, which allowed for the sale of up to $21.225 million worth of shares [17]. Debt Settlement - Quantum BioPharma has settled $260,000 owed to an arm's length creditor by issuing 17,626 Class B Subordinate Voting Shares at a deemed price of $14.75 per share [18]. Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing myelin degradation associated with multiple sclerosis [19]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until reaching $250 million, after which the royalty will drop to 3% [19].

Core Insights - Quantum BioPharma Ltd. is involved in a USD $700 million lawsuit against CIBC and RBC, alleging stock market manipulation through "stock spoofing" [2][3] - The company emphasizes the importance of addressing stock market manipulation for the benefit of shareholders and the integrity of publicly traded companies [3] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative treatments for neurodegenerative and metabolic disorders, including multiple sclerosis (MS) [4] - The company is developing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation in MS [4] - Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is associated with its product unbuzzd™ and has a royalty agreement that could yield up to $250 million [4] Legal and Regulatory Context - The investigative series by CTV News highlights a trend of increasing market manipulation cases in Canada, underscoring the relevance of Quantum BioPharma's legal actions [2][3] - The company is actively encouraging whistleblowers to come forward with information regarding illegal market manipulation, offering rewards up to USD $7 million [3]

Core Insights - Quantum BioPharma Ltd. is involved in a significant legal battle against CIBC and RBC, alleging stock market manipulation through "stock spoofing," which has led to a USD $700 million lawsuit [2][4]. - The investigative series aired by CTV News highlights the impact of stock spoofing on retail investors and the broader implications for market integrity [2][4]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, showing promise in reversing nerve cell degradation associated with multiple sclerosis [5]. - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that could yield up to $250 million [5]. Legal Context - The lawsuit against CIBC and RBC is based on allegations that these banks facilitated stock spoofing, with claims that over 16 million illegal orders were placed through their trading platforms [4]. - The company aims to use the exposure from the lawsuit to protect other firms and investors from similar experiences of market manipulation [4].